To facilitate the rapid progression of novel new drugs into clinical trials, our group focuses on new mechanistic studies and lead compound development necessary for the initial phases of drug development. We work on key facets of drug development that include mechanistic studies disease indications, clinical validations, structural analyses, and biomarkers for lead compound development.